Shots:

• The companies collaborated to develop Turnstone’s pipeline of selected TILs for the identification, enrichment, and expansion of neoantigen reactive TILs in a solid tumor, including melanoma, colorectal cancers, and other indications
• Moffitt to get Turnstone’s TIL manufacturing process from Turnstone to produce cell products for further clinical studies of TIL product while Turnstone will provide financial support for research and development
• Turnstone will submit IND submission of its TIDAL-01 & is expected to enter the clinic in early 2022. Additionally, Turnstone focuses on clinical efficacy to treat lower mutational burden cancer indications with its TIL platform

Ref: Business Wire | Image: Turnstone Biologics